Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants…
PROCPlatinum Resistant Ovarian CancerEndometrial Cancer
Whitehawk Therapeutics, Inc.NCT07470853
Phase 1
A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conj…
Endometrial CancerOvarian CancerOvarian Cancer Metastatic+4 more
Whitehawk Therapeutics, Inc.NCT07444814
Phase 2
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.
Platinum Resistant Ovarian Cancer
Massachusetts General HospitalNCT07265739
Phase 1
A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. …
Ovarian Cancer RecurrentOvarian CancerPlatinum Resistant Ovarian Cancer
Outpace Bio, Inc.NCT07030907